Skip to main content
Back
ABT logo

Abbott Laboratories

Data quality: 100%
ABT
NYSE Healthcare Medical - Devices
$104.85
▼ $0.61 (-0.58%)
Mkt Cap: 182.20B
Day Range
$104.10 $107.07
52-Week Range
$104.10 $139.06
Volume
5,891,472
50D / 200D Avg
$113.11 / $125.68
Prev Close
$105.46

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 27.9 0.4
P/B 3.5 2.9
ROE % 13.1 3.7
Net Margin % 14.7 3.8
Rev Growth 5Y % 0.7 10.0
D/E 0.3 0.2

Insider Trading Activity

Buy ratio (90d) 0.0%
20 transactions
Date Insider Type Shares Price Value
Mar 2, 2026
Shroff Eric
Senior Vice President
sell 709 $115.58 $81,946
Mar 2, 2026
Cushman Elizabeth C.
EVP, GC AND SECRETARY
sell 263 $115.58 $30,398
Mar 2, 2026
Morrone Louis H.
EXECUTIVE VICE PRESIDENT
sell 1,144 $115.58 $132,224
Feb 27, 2026
Shroff Eric
Senior Vice President
other 1,384 $116.26 $160,904
Feb 27, 2026
Boudreau Philip P
EVP AND CFO
other 7,441 $116.26 $865,091
Feb 27, 2026
Ford Robert B
CHAIRMAN AND CEO
other 30,308 $116.26 $3,523,608
Feb 27, 2026
Cushman Elizabeth C.
EVP, GC AND SECRETARY
other 1,421 $116.26 $165,205
Feb 27, 2026
Morrone Louis H.
EXECUTIVE VICE PRESIDENT
other 4,040 $116.26 $469,690
Feb 24, 2026
Ford Robert B
CHAIRMAN AND CEO
grant 427,530
Dec 31, 2025
Stratton John G
grant 313 $125.29 $39,216
Dec 31, 2025
Roman Michael F
grant 301 $125.29 $37,712
Dec 11, 2025
Salvadori Daniel Gesua Sive
EVP AND GROUP PRESIDENT
other 1,536 $123.28 $189,358
Sep 30, 2025
Stratton John G
grant 293 $133.94 $39,244
Jun 30, 2025
Stratton John G
grant 282 $136.01 $38,355
Jun 30, 2025
Morrone Louis H.
EXECUTIVE VICE PRESIDENT
other 269 $134.38 $36,148
Jun 30, 2025
Gonzalez Patricia Paola
grant 242 $136.01 $32,914
Apr 30, 2025
Blount Sally E.
sell 2,600 $129.66 $337,116
Apr 25, 2025
Roman Michael F
grant 1,635
Apr 25, 2025
McDew Darren W
grant 1,635
Mar 31, 2025
Gonzalez Patricia Paola
grant 248 $132.65 $32,897

Key Takeaways

Revenue grew 0.72% annually over 5 years — modest growth
Earnings declined -51.32% over the past year
ROE of 13.07% — decent returns on equity
Debt/Equity of 0.29 — conservative balance sheet
Generating 7.40B in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 4.95%

Growth

Revenue Growth (5Y)
0.72%
Revenue (1Y)5.67%
Earnings (1Y)-51.32%
FCF Growth (3Y)20.90%

Quality

Return on Equity
13.07%
ROIC8.98%
Net Margin14.72%
Op. Margin18.16%

Safety

Debt / Equity
0.29
Current Ratio1.58
Interest Coverage23.60

Valuation

P/E Ratio
27.93
P/B Ratio3.50
EV/EBITDA23.45
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 5.67% Revenue Growth (3Y) 5.13%
Earnings Growth (1Y) -51.32% Earnings Growth (3Y) 6.77%
Revenue Growth (5Y) 0.72% Earnings Growth (5Y) -1.99%
Profitability
Revenue (TTM) 44.33B Net Income (TTM) 6.52B
ROE 13.07% ROA 7.52%
Gross Margin 55.51% Operating Margin 18.16%
Net Margin 14.72% Free Cash Flow (TTM) 7.40B
ROIC 8.98% FCF Growth (3Y) 20.90%
Safety
Debt / Equity 0.29 Current Ratio 1.58
Interest Coverage 23.60 Dividend Yield 0.02%
Valuation
P/E Ratio 27.93 P/B Ratio 3.50
P/S Ratio 4.11 PEG Ratio -0.65
EV/EBITDA 23.45 Dividend Yield 0.02%
Market Cap 182.20B Enterprise Value 188.74B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 44.33B 41.95B 40.11B 43.65B 43.08B
Net Income 6.52B 13.40B 5.72B 6.93B 7.07B
EPS (Diluted) 3.72 7.64 3.27 3.91 3.94
Gross Profit 24.61B 21.33B 20.04B 22.32B 23.21B
Operating Income 8.05B 6.83B 6.44B 8.36B 9.20B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 86.71B 81.41B 73.21B 74.44B 75.20B
Total Liabilities 33.94B 33.51B 34.39B 37.53B 39.17B
Shareholders' Equity 52.13B 47.66B 38.60B 36.69B 35.80B
Total Debt 15.07B 15.28B 15.87B 17.95B 19.25B
Cash & Equivalents 8.52B 7.62B 6.90B 9.88B 9.80B
Current Assets 26.00B 23.66B 22.67B 25.22B 24.24B
Current Liabilities 16.50B 14.16B 13.84B 15.49B 13.11B

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#685 of 1024
37

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026